These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30398699)

  • 1. Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs.
    Hewlett S; Haig-Ferguson A; Rose-Parfitt E; Halls S; Freke S; Creamer P
    Musculoskeletal Care; 2019 Mar; 17(1):63-71. PubMed ID: 30398699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
    Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
    Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial).
    Uhrenholt L; Schlemmer A; Hauge EM; Christensen R; Dreyer L; Suarez-Almazor ME; Kristensen S
    BMJ Open; 2019 Jul; 9(7):e028517. PubMed ID: 31292181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment.
    Chen MH; Lee MH; Liao HT; Chen WS; Lai CC; Tsai CY
    Clin Rheumatol; 2018 Feb; 37(2):429-438. PubMed ID: 29307092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
    Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
    Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Useful message in choosing optimal biological agents for patients with autoimmune arthritis.
    Lai JH; Ling XC; Ho LJ
    Biochem Pharmacol; 2019 Jul; 165():99-111. PubMed ID: 30876919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives.
    Chan SJ; Stamp LK; Liebergreen N; Ndukwe H; Marra C; Treharne GJ
    Patient; 2020 Apr; 13(2):225-234. PubMed ID: 31802391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion.
    de Carvalho JF; Dos Santos MNP; de Oliveira JMV; Lanty Silva ANS; de Araujo RPC; Cardozo JB
    Adv Rheumatol; 2018 Aug; 58(1):22. PubMed ID: 30657070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.
    Valero M; Sánchez-Piedra C; Freire M; Colazo M; Busquets N; Meriño-Ibarra E; Rodríguez-Lozano C; Manrique S; Campos C; Sánchez-Alonso F; Castrejón I
    Arthritis Res Ther; 2023 May; 25(1):86. PubMed ID: 37217997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
    Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
    Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What do Australian patients with inflammatory arthritis value in treatment? A discrete choice experiment.
    Ho KA; Acar M; Puig A; Hutas G; Fifer S
    Clin Rheumatol; 2020 Apr; 39(4):1077-1089. PubMed ID: 31858340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
    Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
    Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics in Inflammatory and Immunomediated Arthritis.
    Luchetti MM; Benfaremo D; Gabrielli A
    Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why Do Patients with Chronic Inflammatory Rheumatic Diseases Discontinue Their Biologics? An Assessment of Patients' Adherence Using a Self-report Questionnaire.
    Betegnie AL; Gauchet A; Lehmann A; Grange L; Roustit M; Baudrant M; Bedouch P; Allenet B
    J Rheumatol; 2016 Apr; 43(4):724-30. PubMed ID: 26879361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualitative assessment of medication adherence in patients with rheumatic diseases on biologic therapy.
    Raghunath S; Hijjawi R; Hoon E; Shanahan EM; Goldblatt F
    Clin Rheumatol; 2019 Oct; 38(10):2699-2707. PubMed ID: 31172365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.